2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 455

Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Abstract Number: 2571

Lack of Control of Hypertension in Systemic Lupus Erythematosus
Abstract Number: 1726

Lack of Correlation Between Mannose-Binding Lectin Gene Polymorphisms and the Thickness of the Carotid Artery Intima-Media (IMT) in Primary Antiphspholipid Syndrome
Abstract Number: 139

Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout
Abstract Number: 7

Lamin A Deregulation in Human Mesenchymal Stem Cells Promotes an Impairment in Their Chondrogenic Potential and Imbalance in Their Response to Oxidative Stress
Abstract Number: 2451

Laquinimod (LAQ) Is Equivalent to Mycophenolate Mofetil (MMF) in Preventing and Suppressing Murine Lupus Nephritis and Has Greater Effects On Myeloid/Monocyte/Macrophage Cells
Abstract Number: 2358

Large Vessel Giant Cell Arteritis: A Cohort Study
Abstract Number: 1482

Laser Speckle Contrast Imaging May Help in the Differential Diagnosis of Raynaud’s Phenomenon
Abstract Number: 450

Late Onset Neutropenia After Rituximab Treatment for Rheumatological Conditions
Abstract Number: 1427

Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant?
Abstract Number: 1818

Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
Abstract Number: 173

Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work?
Abstract Number: 1105

Lateral Tibio-Femoral Shift Related to Medial Knee Osteoarthritis
Abstract Number: 956

Learning Disability in Fibromyalgia Patients: FMS Patients Report More Language and Spatial Difficulties
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk I
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk II
Abstract Number: 1458

Left Ventricular Diastolic Dysfunction May Play a Role in Pathophysiology and Poor Prognosis of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Abstract Number: 720

Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Abstract Number: 791

Leg Muscle Mass Is Not Affected by Foot Pain, Structure or Function: The Framingham Foot Study
Abstract Number: 74

Length of Stay for Rheumatoid Arthritis Related Orthopedic Surgery Has Improved Over the Past 3 Decades and Is Related to Disease Markers. Results From Two UK Multicentre Inception Cohorts (1986-2011) Compared with National Data
Abstract Number: 666

Leukadherin 1, a CR3 Mimetic, Negatively Regulates Toll Like Receptor (TLR) Dependent Inflammatory Responses via Degradation of an Adaptor Protein
Abstract Number: 29

Level of IL-1â-Induced Epigenetic Modifications Differ in Chondrocytes From Different Histological Zones of Human Cartilage
Abstract Number: 818

Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Abstract Number: 599

LIGHT (TNFSF14), Cathepsin K, DKK-1 and Sclerostin in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST Imbalance Unrelated to Disease Activity and Effect of ANTI-TNFα Treatment On the WNT/β Catenin Pathway
Abstract Number: 498

LIGHT (TNFSF14), Cathepsin-K, DKK-1 and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling
Abstract Number: 2259

Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey
Abstract Number: 1459

Limited Utility of Pulmonary Function Tests and B-Type Natriuretic Peptide As Screening Tools for Pre-Capillary Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 714

Line Blot Assay, a Screening Test for Autoantibodies in Systemic Sclerosis (SSc)
Abstract Number: 1268

Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis
Abstract Number: 1265

Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study
Abstract Number: 348

Liver Fibrosis Evaluated by Shearwave Elastograpy Is Associated with Body Mass Index and Serum AST, but Not Methotrexate Cumulative Dose and Duration in Patients with Rheumatoid Arthritis
Abstract Number: 1822

Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
Abstract Number: 2612

Localisation of Bone Marrow Edema in Sacroiliac Joints in Spondyloarthritis Patients: Does the Site of Lesions Change Over a 3-Month Period?
Abstract Number: 1020

Location of Erosions At the Metatarsophalangeal Joints in Patients with Rheumatoid Arthritis
Abstract Number: 1582

Long Term Costs and Cost-Effectiveness of an Integrated Rehabilitation Programme for Chronic Knee Pain
Abstract Number: 574

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis
Abstract Number: 227

Long Term Outcome of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies and Amyopathic Dermatomyositis
Abstract Number: 41

Long-Distance Physical Connections Between Chondrocytes; Cell-to-Cell Communication within Articular Cartilage
Abstract Number: 1318

Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Abstract Number: 2195

Long-Term Changes in Autoantibody Profile After Pandemic Unadjuvanted Influenza A/H1N1 Vaccine in Sjögren’s Syndrome
Abstract Number: 185

Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
Abstract Number: 194

LONG-TERM Efficacy of Tocilizumab in A Patient with Amyloidosis and Interstitial Pneumonia Secondary to Multicentric Castleman’s Disease (MCD)
Abstract Number: 454

Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
Abstract Number: 1545

Long-Term Follow-up of 118 Polyarteritis Nodosa and Microscopic Polyangiitis without Poor-Prognosis Factors
Abstract Number: 1917

Long-Term Follow-up of IgG4-Related Diseases Presenting with Lacrimal and Salivary Gland Involvement
Abstract Number: 2676

Long-Term Humoral Autoimmunity to Ro60 in Primary Sjögren’s Syndrome Is Driven by Clonal Succession
Abstract Number: 186

Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Abstract Number: 1544

Long-Term Outcome of Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Rituximab
Abstract Number: 290

Long-Term Outcomes in Neonatal Lupus
Abstract Number: 1428

Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus
Abstract Number: 775

Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Abstract Number: 1550

Long-Term Outcomes of Patients with Reversible Cerebral Vasoconstriction Syndromes (RCVS)
Abstract Number: 1316

Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Abstract Number: 447

Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study
Abstract Number: 144

Long-Term Safety of Canakinumab in Patients with Gouty Arthritis
Abstract Number: 1149

Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 459

Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
Abstract Number: 1640

Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Abstract Number: 259

Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results
Abstract Number: 1304

Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Abstract Number: 653

Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare
Abstract Number: 2205

Longitudinal Evaluation of the Performance of Different Classification Criteria in Patients with Primary Sjögren’s Syndrome
Abstract Number: 86

Longitudinal Hypertension Diagnosis and Control Among a Primary Care Medically Homed Population with Rheumatoid Arthritis
Abstract Number: 1935

Longitudinal Peripheral Blood Lymphocyte Subsets Correlate with Decreased Disease Activity in Juvenile Dermatomyositis
Abstract Number: 2679

Loss of Caspase 8 in Dendritic Cells Induces a Systemic Lupus Erythematosus-Like Disease That Is Independent of the Necroptosome
Abstract Number: 420

Loss-of-Co-Homozygosity Mapping and Exome Sequencing of a Syrian Pedigree Identified the Candidate Causal Mutation Associated with Rheumatoid Arthritis
Abstract Number: 1981

Low Body Mass Index, Medication Use and Social Factors Such As Smoking but Not Secondary Medical Disorders or Older Age May Be More Prevalent in Males with Low Bone Mineral Density
Abstract Number: 923

Low Bone Mineral Density and Higher Parathyroid Hormone Levels As Independent Factors to All-Cause Mortality in Community-Dwelling Older Adults: the São Paulo Ageing & Health Study (SPAH)
Abstract Number: 1511

Low Circulating Endothelial Progenitor Cell Levels and High VEGF Serum Levels Are Associated with the Late Nailfold Capillaroscopic Pattern in Systemic Sclerosis
Abstract Number: 2515

Low Density Lipoprotein Receptor Deficiency Results in Osteophyte Formation During Experimental Osteoarthritis Which Is Enhanced Under High Cholesterol Conditions
Abstract Number: 2227

Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Abstract Number: 835

Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients
Abstract Number: 1959

Low Fracture Incidence Is Maintained in Postmenopausal Women ≥75 Years with Osteoporosis with Long-Term Denosumab Treatment
Abstract Number: 2282

Low Gene Copy Number for C4, C4A and C4B Is a Strong Risk Factor for Developing Systemic Lupus Erythematosus in Childhood
Abstract Number: 1221

Low Muscle Density in Rheumatoid Arthritis and Modified Association with Total Fat Mass, Results of a Pilot Study
Abstract Number: 2078

Low-Density Lipoprotein Receptor Deficiency Ameliorates the Development of Inflammatory Arthritis
Abstract Number: 166

Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Vs Normal Renal Function
Abstract Number: 1151

Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide
Abstract Number: 1096

Lower Income Paradoxically Associated with Better Patient-Reported Outcomes After Knee Arthroplasty in the U.S
Abstract Number: 1841

Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients
Abstract Number: 2339

Lowering Fli1 Levels Decreases the Levels of Lipid Mediators in the Kidneys and T Cells of MRL/Lpr Lupus Prone Mice
Abstract Number: 2435

Lumbrical Splinting and Stretching Versus Standard Treatment On Grip, Pinch, and Dexterity in People with Carpal Tunnel Syndrome
Abstract Number: 1692

Lung Microbiome Differs in Subjects with Rheumatoid Arthritis-Related Autoimmunity without Inflammatory Arthritis Compared to Healthy Seronegative Controls
Abstract Number: 222

Lung Nodules in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1648

Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss
Abstract Number: 2618

Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy
Abstract Number: 1440

Lupus-Prone Mice Demonstrate Enhanced Neutrophil Extracellular Trap Formation: Implications for Autoantibody Formation and Organ Damage
Abstract Number: 2570

Lymphoma Risk in Systemic Lupus: Effects of Disease Activity Versus Treatment

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].